Anticonvulsant and acute adverse effect profiles of picolinic acid 2-fluoro-benzylamide in various experimental seizure models and chimney test in mice

Fundamental and Clinical Pharmacology

Volumn 22, Issue 1, 2008, Pages 69-74

  Luszczki, Jarogniew J ^a,b   Swiader, Mariusz J ^a   Swiader, Katarzyna ^a   Paruszewski, Ryszard ^c   Turski, Waldemar A ^a,b   Czuczwar, Stanislaw J ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

AMPA; Bicuculline; Chimney test; Kainic acid; Maximal electroshock seizure test; NMDA; Pentylenetetrazole; Picolinic acid 2 fluoro benzylamide; Pilocarpine; Protective index

Indexed keywords

2 FLUORO BENZYLAMIDE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; BICUCULLINE; KAINIC ACID; N METHYL DEXTRO ASPARTIC ACID; PENTETRAZOLE; PICOLINIC ACID DERIVATIVE; PILOCARPINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; ELECTRIC SHOCK; EXPERIMENTAL TEST; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEIZURE;

ANIMALS; ANTICONVULSANTS; BENZYL COMPOUNDS; DISEASE MODELS, ANIMAL; MALE; MICE; MOTOR SKILLS; PICOLINIC ACIDS; SEIZURES;

EID: 38649114663     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2007.00547.x     Document Type: Article

References (22)

1. Engelborghs S., D'Hooge R., De Deyn P.P. Pathophysiology of epilepsy. Acta Neurol. Belg. (2000) 100 201 213.
2. Holmes G.L. Epilepsy in the developing brain: lessons from the laboratory and clinic. Epilepsia (1997) 38 12 30.
3. Löscher W. Influence of pharmacological manipulation of inhibitory and excitatory neurotransmitter systems on seizure behavior in the Mongolian gerbil. J. Pharmacol. Exp. Ther. (1985) 233 204 213.
4. Meldrum B.S. Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J. Nutr. (2000) 130 (4S Suppl) 1007S 1015S.
5. Ueda Y., Tsuru N. Simultaneous monitoring of the seizure-related changes in extracellular glutamate and gamma-aminobutyric acid concentration in bilateral hippocampi following development of amygdaloid kindling. Epilepsy Res. (1995) 20 213 219.
6. White H.S., Wolf H.H., Woodhead J.H., Kupferberg H.J. The National Institutes of Health Anticonvulsant Drug Development Program: screening for efficacy. Adv. Neurol. (1998) 76 29 39.
7. White H.S., Woodhead J.H., Wilcox K.S., Stables J.P., Kupferberg H.J., Wolf H.H. General principles: discovery and preclinical development of antiepileptic drugs, in: Levy R.H., Mattson R.H., Meldrum B.S., Perucca E. (Eds Antiepileptic drugs. 5th edn, Lippincott Williams & Wilkins, Philadelphia, PA, 2000, pp. 36 48.
8. Kwan P., Brodie M.J. Early identification of refractory epilepsy. N. Engl. J. Med. (2000) 342 314 319.
9. Swinyard E.A. Laboratory evaluation of antiepileptic drugs: review of laboratory methods. Epilepsia (1969) 10 107 119.
10. Paruszewski R., Strupinska M., Stables J.P. et al. Amino acid derivatives with anticonvulsant activity. Chem. Pharm. Bull. (Tokyo) (2001) 49 629 631.
11. Paruszewski R., Strupinska M., Rostafinska-Suchar G., Stables J.P. New derivatives of picolinic acid and nicotinic acid with anticonvulsant activity. Protein Pept. Lett. (2005) 12 701 704.
12. Swiader M.J., Luszczki J.J., Paruszewski R., Czuczwar S.J., Turski W.A. Anticonvulsant and acute neurotoxic characteristics of nicotinic acid benzylamide: a preclinical study. Pharmacol. Rep. (2006) 58 431 434.
13. Litchfield J.T., Wilcoxon F. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. (1949) 96 99 113.
14. Luszczki J.J., Czuczwar S.J. Gabapentin synergistically interacts with topiramate in the mouse maximal electroshock seizure model: an isobolographic analysis. Pharmacol. Rep. (2006) 58 944 954.
15. Luszczki J.J., Czuczwar M., Gawlik P. et al. Influence of N(G)-nitro-L-arginine on the anticonvulsant and acute adverse effects of some newer antiepileptic drugs in the maximal electroshock-induced seizures and chimney test in mice. Pharmacol. Rep. (2006) 58 955 960.
16. Löscher W., Fassbender C.P., Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res. (1991) 8 79 94.
17. Boissier J.R., Tardy J., Diverres J.C. Une nouvelle methode simple pour explorer l'action "tranquilisante": Le test de la cheminee. Med. Exp. (1960) 3 81 84.
18. Luszczki J.J., Kozicka M., Swiader M.J., Czuczwar S.J. 2-Chloro-N6-cyclopentyladenosine enhances the anticonvulsant action of carbamazepine in the mouse maximal electroshock-induced seizure model. Pharmacol. Rep. (2005) 57 787 794.
19. Löscher W., Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. IV. Protective indices. Epilepsy Res. (1991) 9 1 10.
20. Czuczwar S.J., Meldrum B. Protection against chemically induced seizures by 2-amino-7-phosphonoheptanoic acid. Eur. J. Pharmacol. (1982) 83 335 338.
21. Tutka P., Klonowski P., Dzieciuch J., Kleinrok Z., Czuczwar S.J. NG-nitro-L-arginine differentially affects glutamate- or kainate-induced seizures. Neuroreport (1996) 7 1605 1608.
22. Turski W.A., Cavalheiro E.A., Coimbra C., da Penha Berzaghi M., Ikonomidou-Turski C., Turski L. Only certain antiepileptic drugs prevent seizures induced by pilocarpine. Brain Res. (1987) 434 281 305.